Nitib 140 mg (Ibrutinib)
| Active Ingredient | Ibrutinib |
|---|---|
| Indication: | Mantle-cell lymphoma, Blood cancer (Chronic lymphocytic leukemia) |
| Manufacturer: | Hetero Drugs Ltd |
| Packaging | 30 capsules in 1 bottle |
| Strength | 140mg |
| Delivery Time | 6 To 15 days |
Nitib 140 mg contains Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor used in treating certain blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström’s macroglobulinemia. It blocks cancer cell signals that cause growth and division. Nitib is taken orally once daily, often as part of long-term targeted therapy. Common side effects include diarrhea, fatigue, bruising, or infections. Serious risks include heart rhythm issues and bleeding. Regular blood tests and ECG monitoring may be needed. Always take under oncologist supervision. Do not skip or stop without medical guidance.








There are no reviews yet.